Skip to content

Intermittent Preventive Treatment in Infant in Mali

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00766662
Enrollment
Unknown
Registered
2008-10-06
Start date
2006-10-31
Completion date
2007-12-31
Last updated
2008-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Keywords

Malaria, Intermittent Preventive Treatment, EPI vaccine coverage, Resistance of P. falciparum to Sulfadoxine- Pyrimethamine

Brief summary

Studies have shown that Intermittent preventive treatment in infants (IPTi) with Sulfadoxine-pyrimethamine (SP)reduced the incidence of clinical malaria and anemia without modifying infants' serological response to EPI vaccines. Thus IPTi was seen as a potential public health tool of great benefit to the children of Africa and a logical addition to the Immunization Plus package. The objectives of this operational researcher were * to develop an implementation model for IPTi in the health care system in Mali * to assess its impact on the EPI vaccines and other health interventions coverage * and on molecular makers of resistance to SP

Detailed description

The study was implemented in districts of the region of Koulikoro; the district of Koulikoro and the district of Kolokani. The whole district of Koulikoro was covered by the intervention while in Kolokani, the 22 health areas (sub districts) were randomized in 1:1 ratio with the intervention in 11 health areas and the other 11 serving as control for the assessment of the impact of IPTi implementation on EPI vaccines and other health interventions coverage as well as its impact on the resistance to SP. The implementation consisted of administration of ½ tablet of Sulfadoxine -Pyrimethamine with EPI vaccines (DTP2, DTP3 and Measles vaccine) from December 2006 to December 2007.

Interventions

Sponsors

UNICEF
CollaboratorOTHER
University of Bamako
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 23 Months
Healthy volunteers
Yes

Inclusion criteria

* Resident of Kolokani, Mali * Age less than 24 months

Exclusion criteria

* Not Resident of Kolokani * Age of 24 months or above

Design outcomes

Primary

MeasureTime frame
EPI vaccines and other health interventions coverage1 year
Molecular makers of resistance of P. falciparum to Sulfaxodine- pyrimethamine1 year

Countries

Mali

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026